Skip to main content
. 2014 May 6;16(3):235–246.e1. doi: 10.1016/j.neo.2014.03.005

Figure 4.

Figure 4

Sunitinib treatment results in strong reduction of angiogenesis and blocks invasion of s.c. HaCaT-ras A-5RT3 tumors. Quantification of immunostainings for CD31 and VEGFR2 demonstrates the significant reduction in vessel density (A) and angiogenic activity (B) in sunitinib-treated tumors (n = 5) compared with untreated controls (n = 4). (C) Representative immunostainings for CD31 (green), VEGFR2 (red), keratin (PK; blue), or DAPI (blue), respectively, of an untreated control and sunitinib-treated tumor. Right panels (bar, 50 μm) are magnified selected areas of the left panels (bar, 200 μm) (indicted by a red square). Data are presented as means ± SD. (***P < .001).